Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.
Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, Scholtes C, Roche B, Castelnau C, Poynard T, Chazouillères O, Ganne N, Fontaine H, Gournay J, Guyader D, Le Gal F, Nahon P, Roudot-Thoraval F, Gordien E; Deltavir study group. Roulot D, et al. Among authors: castelnau c. J Hepatol. 2020 Nov;73(5):1046-1062. doi: 10.1016/j.jhep.2020.06.038. Epub 2020 Jul 4. J Hepatol. 2020. PMID: 32634548 Free article.
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, et al. Martinot-Peignoux M, et al. Among authors: castelnau c. Hepatology. 1995 Oct;22(4 Pt 1):1050-6. Hepatology. 1995. PMID: 7557850 Clinical Trial.
Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.
Martinot M, Marcellin P, Boyer N, Detmer J, Pouteau M, Castelnau C, Degott C, Aupérin A, Collins M, Kolberg J, Wilber J, Benhamou JP, Erlinger S. Martinot M, et al. Among authors: castelnau c. Ann Intern Med. 1997 Jun 1;126(11):874-81. doi: 10.7326/0003-4819-126-11-199706010-00004. Ann Intern Med. 1997. PMID: 9163288
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Marcellin P, et al. Among authors: castelnau c. Ann Intern Med. 1997 Nov 15;127(10):875-81. doi: 10.7326/0003-4819-127-10-199711150-00003. Ann Intern Med. 1997. PMID: 9382365
Re-treatment with interferon alfa of patients with chronic hepatitis C.
Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, Maghinici C, Sinegre M, Benhamou JP, Degott C, Erlinger S, Marcellin P. Chow WC, et al. Among authors: castelnau c. Hepatology. 1998 Apr;27(4):1144-8. doi: 10.1002/hep.510270432. Hepatology. 1998. PMID: 9537456
[Treatment of chronic hepatitis B].
Asselah T, Castelnau C, Boyer N, Ripault MP, Marcellin P. Asselah T, et al. Among authors: castelnau c. Gastroenterol Clin Biol. 2004 Dec;28(12):1215-27. doi: 10.1016/s0399-8320(04)95213-x. Gastroenterol Clin Biol. 2004. PMID: 15671931 Free article. Review. French. No abstract available.
Natural history of hepatitis B.
Marcellin P, Castelnau C, Martinot-Peignoux M, Boyer N. Marcellin P, et al. Among authors: castelnau c. Minerva Gastroenterol Dietol. 2005 Mar;51(1):63-75. Minerva Gastroenterol Dietol. 2005. PMID: 15756147 Review.
54 results